Portenoy R K
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Semin Oncol. 1995 Apr;22(2 Suppl 3):112-20.
More than three quarters of cancer patients experience chronic pain during the course of their disease. With optimal pharmacotherapy alone, 70% to 90% could achieve adequate relief. Optimal pharmacotherapy begins with a comprehensive pain assessment, which defines the nature of the pain complaint and clarifies the degree to which pain and other factors contribute to impaired quality of life. Although the potential analgesic consequences of primary therapy are always considered, only radiotherapy is used commonly. Patients with persistent moderate to severe pain should be treated with an appropriate opioid regimen, which is based on careful selection of an opioid drug and route of administration, individualization of the dose through titration based on repeated assessment of the patient, and ongoing efforts to manage side effects. The use of adjuvant analgesics and the use of sequential opioid trials may improve the outcome of therapy for patients who fail to promptly attain a favorable balance between analgesia and side effects during an opioid trial.
超过四分之三的癌症患者在患病过程中会经历慢性疼痛。仅采用最佳药物治疗,70%至90%的患者能够获得充分缓解。最佳药物治疗始于全面的疼痛评估,该评估可确定疼痛主诉的性质,并阐明疼痛及其他因素对生活质量受损的影响程度。虽然始终会考虑初始治疗的潜在镇痛效果,但通常仅使用放射疗法。持续性中度至重度疼痛的患者应采用适当的阿片类药物治疗方案,该方案基于对阿片类药物及给药途径的谨慎选择、通过根据对患者的反复评估进行滴定来实现剂量个体化,以及持续努力管理副作用。对于在阿片类药物试验期间未能迅速在镇痛和副作用之间达到良好平衡的患者,使用辅助镇痛药和进行序贯阿片类药物试验可能会改善治疗效果。